AU9386398A - Cysteine rich receptors: trail - Google Patents

Cysteine rich receptors: trail

Info

Publication number
AU9386398A
AU9386398A AU93863/98A AU9386398A AU9386398A AU 9386398 A AU9386398 A AU 9386398A AU 93863/98 A AU93863/98 A AU 93863/98A AU 9386398 A AU9386398 A AU 9386398A AU 9386398 A AU9386398 A AU 9386398A
Authority
AU
Australia
Prior art keywords
trail
cysteine rich
receptors
rich receptors
cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU93863/98A
Other languages
English (en)
Inventor
Jurg Tschopp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of AU9386398A publication Critical patent/AU9386398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU93863/98A 1997-09-12 1998-09-11 Cysteine rich receptors: trail Abandoned AU9386398A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5863197P 1997-09-12 1997-09-12
US60058631 1997-09-12
US8442298P 1998-05-06 1998-05-06
US60084422 1998-05-06
PCT/US1998/019029 WO1999012963A2 (en) 1997-09-12 1998-09-11 Cysteine rich receptors: trail

Publications (1)

Publication Number Publication Date
AU9386398A true AU9386398A (en) 1999-03-29

Family

ID=26737837

Family Applications (2)

Application Number Title Priority Date Filing Date
AU92303/98A Ceased AU738688B2 (en) 1997-09-12 1998-09-11 Cysteine rich receptors-train
AU93863/98A Abandoned AU9386398A (en) 1997-09-12 1998-09-11 Cysteine rich receptors: trail

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU92303/98A Ceased AU738688B2 (en) 1997-09-12 1998-09-11 Cysteine rich receptors-train

Country Status (9)

Country Link
US (4) US7223852B2 (enExample)
EP (2) EP1012179A2 (enExample)
JP (1) JP4357738B2 (enExample)
AT (1) ATE360032T1 (enExample)
AU (2) AU738688B2 (enExample)
CA (1) CA2301173C (enExample)
DE (1) DE69837606T2 (enExample)
ES (1) ES2286856T3 (enExample)
WO (2) WO1999012963A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
KR20000075749A (ko) * 1997-02-27 2000-12-26 오노 야꾸힝 고교 가부시키가이샤 신규의 폴리펩티드, 그 폴리펩티드를 암호하는 ｄｎａ 및 그용도
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
ES2286856T3 (es) 1997-09-12 2007-12-01 Biogen Idec Ma Inc. Receptores train ricos en cisteina.
IL136988A0 (en) * 1997-12-29 2001-06-14 Regeneron Pharma Novel nucleic acid and polypeptide
EP1053351A4 (en) * 1998-01-27 2002-09-25 Millennium Pharm Inc NOVEL TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMIL MOLECULES AND USES THEREOF
AU2486300A (en) * 1998-12-30 2000-07-31 Millennium Pharmaceuticals, Inc. Secreted proteins and nucleic acids encoding them
WO2000049149A1 (fr) * 1999-02-19 2000-08-24 Toshio Kitamura Nouvelles proteines du type recepteurs des tnf
JP4787439B2 (ja) 1999-08-17 2011-10-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ）
AU6928200A (en) * 1999-08-25 2001-03-19 Genome Therapeutics Corporation A transmembrane trap for isolating membrane bound proteins
CA2391820A1 (en) * 1999-10-22 2001-05-03 Zymogenetics, Inc. Umlr polypeptides
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
WO2001058954A2 (en) * 2000-02-11 2001-08-16 Genetics Institute, Llc. Trade molecules and uses related thereto
US6900185B1 (en) 2000-04-12 2005-05-31 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
CA2426710A1 (en) * 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
ES2437992T3 (es) 2001-05-25 2014-01-15 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20190357827A1 (en) 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
WO2005092927A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
BRPI0606791A2 (pt) 2005-02-02 2010-02-09 Uab Research Foundation métodos de reverter ou prevenir a resistência de uma célula a um agonista do receptor da morte, de triar uma célula quanto a um biomarcador da resistência a um agonista do receptor da morte, de monitorar a resistência a um agonista do receptor da morte em um indivìduo, de induzir seletivamente a apoptose em uma célula alvo expressando um receptor da morte, de tratar de um indivìduo com cáncer, de tratar de um indivìduo com uma doença inflamatória ou autoimune, de bloquear a ligação da proteìna contendo card a um receptor da morte em uma célula, de bloquear a associação de um iap com o receptor da morte e de triar um modulador de uma proteìna contendo card, composição, ácido nucleico isolado, vetor, célula, e, polipeptìdeo isolado
JP4898126B2 (ja) * 2005-02-28 2012-03-14 中外製薬株式会社 Ｔｒｏｙシグナルが阻害されたトランスジェニック非ヒト動物
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US7888044B2 (en) 2006-04-10 2011-02-15 Trustees Of Boston University Melanoma biomarker and methods of uses
US9149220B2 (en) 2011-04-15 2015-10-06 Dexcom, Inc. Advanced analyte sensor calibration and error detection
KR20120101050A (ko) 2009-11-05 2012-09-12 더 유에이비 리서치 파운데이션 기저형 유전자형 암의 치료 방법
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
RU2644678C1 (ru) 2010-10-29 2018-02-13 Дайити Санкио Компани, Лимитед Новое антитело против dr5
EP4218571B1 (en) 2012-03-16 2025-07-30 Dexcom, Inc. Systems and methods for processing analyte sensor data
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
JP2021500162A (ja) 2017-10-24 2021-01-07 デックスコム・インコーポレーテッド 事前接続された分析物センサ

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5965388A (en) 1996-07-09 1999-10-12 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6261801B1 (en) * 1997-01-14 2001-07-17 Human Genome Sceineces, Inc. Nucleic acids encoding tumor necrosis factor receptor 5
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
KR20000075749A (ko) * 1997-02-27 2000-12-26 오노 야꾸힝 고교 가부시키가이샤 신규의 폴리펩티드, 그 폴리펩티드를 암호하는 ｄｎａ 및 그용도
ES2281126T3 (es) * 1997-03-17 2007-09-16 Human Genome Sciences, Inc. Receptor 5 que contiene un dominio de muerte.
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
ES2286856T3 (es) * 1997-09-12 2007-12-01 Biogen Idec Ma Inc. Receptores train ricos en cisteina.
US20030027272A1 (en) * 1997-09-18 2003-02-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1037899A1 (en) 1997-10-18 2000-09-27 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
IL136988A0 (en) 1997-12-29 2001-06-14 Regeneron Pharma Novel nucleic acid and polypeptide
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
EP1053351A4 (en) 1998-01-27 2002-09-25 Millennium Pharm Inc NOVEL TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMIL MOLECULES AND USES THEREOF
JP2002519062A (ja) 1998-07-06 2002-07-02 シェーリング コーポレイション 哺乳動物遺伝子；樹状細胞プロスタグランジン様トランスポーター（ｄｃ−ｐｇｔ）、ｈｄｔｅａ，ｈｓｌｊｄ３７ｒおよびｒａｎｋｌ、ｈｃｃ５ケモカイン、脱ユビキチン化１１および１２（ｄｕｂ１１、ｄｕｂ１２）、ｍｄ−１、ｍｄ−２およびサイクリンｅ２、関連試薬および方法
JP2000098232A (ja) * 1998-09-25 2000-04-07 Canon Inc 光学素子及びそれを用いた光学系
WO2000049149A1 (fr) 1999-02-19 2000-08-24 Toshio Kitamura Nouvelles proteines du type recepteurs des tnf
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB9927681D0 (en) 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
WO2001058954A2 (en) 2000-02-11 2001-08-16 Genetics Institute, Llc. Trade molecules and uses related thereto
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004506413A (ja) 2000-06-23 2004-03-04 ジェネンテック・インコーポレーテッド 血管形成に関与する疾患の診断と治療のための組成物と方法
EP1354040A2 (en) 2000-07-20 2003-10-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001271973A1 (en) 2000-07-20 2002-02-05 Kevin P. Baker Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2003013578A1 (en) 2001-08-07 2003-02-20 Genset S.A. Omoxin agonists and antagonists for use in the treatment of metabolic disorders
AU2004299044B2 (en) 2003-12-16 2008-10-30 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
US20070186296A1 (en) * 2006-02-02 2007-08-09 Wyeth Cloning, characterization, and application of tnfrsf19 in neurological disorders

Also Published As

Publication number Publication date
ATE360032T1 (de) 2007-05-15
US7223852B2 (en) 2007-05-29
US20090004188A1 (en) 2009-01-01
JP4357738B2 (ja) 2009-11-04
DE69837606T2 (de) 2008-02-14
DE69837606D1 (de) 2007-05-31
EP1012282B1 (en) 2007-04-18
US7402658B2 (en) 2008-07-22
CA2301173C (en) 2015-04-14
US7838639B2 (en) 2010-11-23
US20030219860A1 (en) 2003-11-27
EP1012282A1 (en) 2000-06-28
AU9230398A (en) 1999-03-29
WO1999013078A1 (en) 1999-03-18
WO1999012963A3 (en) 1999-05-06
ES2286856T3 (es) 2007-12-01
JP2002505843A (ja) 2002-02-26
EP1012179A2 (en) 2000-06-28
US20110158993A1 (en) 2011-06-30
US20060233792A1 (en) 2006-10-19
WO1999012963A2 (en) 1999-03-18
AU738688B2 (en) 2001-09-27
HK1028417A1 (en) 2001-02-16
CA2301173A1 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
AU9386398A (en) Cysteine rich receptors: trail
ZA974234B (en) Adhesion receptor antagonists.
AU7268498A (en) Direct keypad back lighting
AU1541599A (en) Modulating b lymphocyte chemokine/receptor interactions
AU4803996A (en) Endothelin receptor antagonists
ZA969775B (en) Endothelin receptor antagonists.
AU4217299A (en) Pth1r and pth3r receptors, methods and uses thereof
AU1620199A (en) G-protein coupled receptors associated with immune response
AU5104799A (en) Novel orphan cytokine receptors
AU2813297A (en) Mammalian mixed lymphocyte receptors, chemokine receptors {mmlr-ccr}
AU1334799A (en) Novel cytokine receptors
AU1535699A (en) Novel receptors opg-2
ZA9811502B (en) Novel composition.
AU6764596A (en) Endothelin receptor antagonists
AU6060796A (en) Endothelin receptor antagonists
ZA966552B (en) Endothelin receptor antagonists.
AU4411699A (en) Interferon receptor hkaef92
AU3543599A (en) Receptors
AU6200296A (en) Endothelin receptor antagonists
AUPP438498A0 (en) Novel Gaba-B receptor
AU5333796A (en) Phenyl derivatives useful as endothelin receptor antagonists
AU6826698A (en) Endothelin receptor antagonists
AU6826498A (en) Endotholin receptor antagonists
AU5758398A (en) Endothelin receptor antagonists as pesticides
HK1028899A (en) Cysteine rich receptors: trail

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase